Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
- Maddalena Centanni, D. Moes, I. Trocóniz, J. Ciccolini, J. V. van Hasselt
- Biology, MedicineClinical Pharmacokinetics
- 28 February 2019
An overview of the pharmacokinetic (PK) aspects related to current ICIs, which include target-mediated drug disposition and time-varying drug clearance, and important issues related to the efficacy and safety, the pharmacodynamics, of ICIs are addressed, including exposure–response relationships related to clinical outcome.
Liposome-encapsulated anticancer drugs: still waiting for the magic bullet?
The achievements, limits, and new expectancies of anticancer drugs as candidates for liposome-encapsulated drugs such as anthracyclines are reviewed.
Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice.
The data-based model development revealed several biologically significant findings, including the postulated link between primary tumor size and emission rate is validated and fast growing peritoneal metastases can only be described by such a complex partial differential equation model and not by ordinary differential equation models.
Computational oncology — mathematical modelling of drug regimens for precision medicine
- D. Barbolosi, J. Ciccolini, B. Lacarelle, F. Barlesi, N. André
- Medicine, BiologyNature Reviews Clinical Oncology
- 1 April 2016
The current achievements and limitations with regard to computational modelling of drug regimens are highlighted, and the potential future implementation of this strategy to achieve precision medicine in oncology is discussed.
Optimization of trans-Resveratrol bioavailability for human therapy.
Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept
This review covers the physicochemistry ofliposomes and the recent technical improvements in the preparation of liposome-encapsulated drugs in regard to the scientific and medical stakes.
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.
Combining radiotherapy with immune checkpoint blockade may offer considerable therapeutic impact if the immunosuppressive nature of the tumor microenvironment (TME) can be relieved. In this study, we…
A simple and rapid high‐performance liquid chromatographic (HPLC) method for 5‐fluorouracil (5‐FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase…
- J. Ciccolini, C. Mercier, M. Blachon, R. Favre, A. Durand, B. Lacarelle
- Medicine, BiologyJournal of Clinical Pharmacy and Therapeutics
- 1 August 2004
Drug monitoring combined with early detection of patients at risk would enable timely dose adaptation so as to maintain drug concentrations within a therapeutic window.
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
It is demonstrated that CDA deficiency, found in 7% of adult patients, is associated with a maximum risk of developing early severe toxicities with gemcitabine, and CDA functional testing could be a simple and easy marker to discriminate adult patients atrisk of developing severe toxicITIES with gem citabine.